Novel Therapies for Relapsed/Refractory Large B-Cell Lymphoma in Community Oncology Practice
Funding Amount
Not stated
Deadline
Deadline not published
Grant Type
Foundation
Can we apply?
Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.
Eligible organizations
- Only organizations are eligible to receive grants, not individuals or physician-owned medical practices or individual-physician-owned organizations
Geography
- Based in the United States
Other requirements
- _You can learn more about this opportunity by visiting the funder's [website](https://www.pfizer.com/about/programs-policies/grants/competitive-grants)._
- The following may apply: medical, nursing, allied health, and/or pharmacy professional schools; hospitals and healthcare institutions (both large and small); professional organizations/medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement
- If the project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project
- For projects offering continuing education credit in the United States, the requesting organization must be accredited
Not eligible / not funded
- Not eligible: It is not our intent to support clinical research projects
- Not eligible: Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered
Overview
Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Novel Therapies for Relapsed/Refractory Large B-Cell Lymphoma in Community Oncology Practice
General Area of Interest for this RFP:
- Projects that will be considered for Pfizer support will focus on increasing community healthcare professional understanding and competence in the following areas:
- Explore treatment options for patients with relapsed/refractory DLBCL, taking into consideration efficacy, safety, and patient-specific factors.
- Therapy management strategies to reduce toxicity and optimize outcomes for patients with R/R DLBCL.
- Mechanisms of drug-resistance/loss of response with emerging treatments.
- Examples of educational formats that will be considered under this RFP include but are not limited to:
- Professional medical society programs with wide reach to community oncologists caring for patients with DLBCL.
- Interactive learning, case-based learning, workshops, tumor boards.
- Digital platforms (e.g., videos, podcasts, infographics, animations, social media-linked content).
- On-agenda educational sessions during local/regional live conferences.
- Grand rounds – single events or series.
- Online articles, newsletter articles, training courses, webinars and downloadable practice resource.
Eligibility
_You can learn more about this opportunity by visiting the funder's website._
- Applicant organizations to this RFP must be based in the United States.
- The following may apply: medical, nursing, allied health, and/or pharmacy professional schools; hospitals and healthcare institutions (both large and small); professional organizations/medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.
- Only organizations are eligible to receive grants, not individuals or physician-owned medical practices or individual-physician-owned organizations.
- If the project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.
- For projects offering continuing education credit in the United States, the requesting organization must be accredited.
Ineligibility
- It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.
What The Pfizer Foundation Inc actually gave
Source: IRS Form 990-PF, 2024
- Grants in 2024
- 9,306
- Total given
- $23.24M
Focus Areas & Funding Uses
Fields of Work
- Healthcare
- Education
Categories
Browse similar grants by category
Related Grants
Open grants from this funder and similar programs
Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple Myeloma Grant
The Pfizer Foundation Inc
Amount
US $50,000 - US $200,000
Deadline
Deadline not published
Pfizer Clostridioides difficile (C. difficile) Research Collaboration Grant
The Pfizer Foundation Inc
Amount
Up to US $500,000
Deadline
Deadline not published
Quality Improvement in Molecular Testing Pathways for Metastatic Colorectal Cancer (mCRC) Grant
The Pfizer Foundation Inc
Amount
US $150,000 - US $250,000
Deadline
Deadline not published
RD Global Monitoring anti-TFPI RES
The Pfizer Foundation Inc
Amount
Varies
Deadline
Deadline not published
Independent Medical Education Grant - Annual Meetings
The Pfizer Foundation Inc
Amount
Varies
Deadline
Deadline not published
Unmet Needs and Emerging Data in Patients with High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Grant
The Pfizer Foundation Inc
Amount
US $50,000 - US $200,000
Deadline
Deadline not published
Ready to apply for Novel Therapies for Relapsed/Refractory Large B-Cell Lymphoma in Community Oncology Practice?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found Novel Therapies for Relapsed/Refractory Large B-Cell Lymphoma in Community Oncology Practice. Now let's win it.